Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Multivalent Filovirus vaccine
- Development stage
- Preclinical
- Lead developer
- Hawaii Biotech
- Modality
- Vaccines & Immunotherapeutics, Recombinant Proteins and Enzymes
- Administration
- Intramuscular, Subcutaneous
01
Overview
**Multivalent Filovirus vaccine** is a preclinical **recombinant subunit protein vaccine** being developed by **Hawaii Biotech** for prevention of **filovirus hemorrhagic fevers**, specifically disease caused by Ebola virus, Sudan virus, and Marburg virus. The vaccine is described as a **multivalent** product incorporating glycoprotein antigens from these three filoviruses, with the intended mechanism of eliciting protective humoral and cellular immune responses against the respective viral envelope glycoproteins and potentially providing broader cross-protective immunity across major filovirus threats.
- Other names
- multivalent filovirus vaccinemultivalent filovirus vaccine ebola sudan marburg
02
Targets
Zaire ebolavirus glycoproteinPYG (Glycogen phosphorylase)
Beyond the preview
Go deeper on Multivalent Filovirus vaccine.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Multivalent Filovirus vaccine.